To this end, the selective, naturally occurring competitive inhibitor of IL-1, interleukin-1 receptor antagonist (IL-1Ra) has shown potential as a new treatment for stroke (Emsley et al., 2005, Banwell et al., 2009, Smith et al., 2012). Here, IL1B is linked to stroke disorder.